We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 29, 2020

Utidelone Plus Capecitabine vs Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Efficacy of Utidelone Plus Capecitabine Versus Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer: Final Analysis of Overall Survival in a Phase 3 Randomised Controlled Trial
Ann. Oncol 2020 Nov 11;[EPub Ahead of Print], B Xu, T Sun, Q Zhang, P Zhang, Z Yuan, Z Jiang, X Wang, S Cui, Y Teng, XC Hu, J Yang, H Pan, Z Tong, H Li, Q Yao, Y Wang, Y Yin, P Sun, H Zheng, J Cheng, J Lu, B Zhang, C Geng, J Liu, K Shen, S Yu, H Li, L Tang, R Qiu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading